

All articles in *Diabetes Care* are available on the World Wide Web at www.diabetes.org/diabetescare. Cover articles (►) are available free of charge. Other articles are available free to print subscribers or can be purchased as PDF files.

Original Articles

Clinical Care/Education/Nutrition

2341 Quality of diabetes care in the middle- and high-income group populace: the Delhi Diabetes Community (DEDICOM) survey

J. Nagpal, A. Bhartia

2349 Parity and risk of type 2 diabetes: the Atherosclerosis Risk in Communities study

W.K. Nicholson, K. Asao, F. Brancati, J. Coresh, J.S. Pankow, N.R. Powe

2355 Durability of insulin pump use in pediatric patients with type 1 diabetes

J.R. Wood, E.C. Moreland, L.K. Volkening, B.M. Svoren, D.A. Butler, L.M.B. Laffel

2361 Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes

C.R. Ong, L.M. Molyneaux, M.I. Constantino, S.M. Twigg, D.K. Yue

2365 Oral treatment with α -lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial

D. Ziegler, A. Ametov, A. Barinov, P.J. Dyck, I. Gurieva, P.A. Low, U. Munzel, N. Yakhno, I. Raz, M. Novosadova, J. Maus, R. Samigullin

2371 Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea

C. Triplitt, L. Glass, Y. Miyazaki, E. Wajcberg, A. Gastaldelli, E. De Filippis, E. Cersosimo, R.A. DeFronzo

2378 Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)

H.A.W. Neil, D.A. DeMicco, D. Luo, D.J. Betteridge, H.M. Colhoun, P.N. Durrington, S.J. Livingstone, J.H. Fuller, G.A. Hitman, on behalf of the CARDS Study Investigators

2385 Does coffee consumption reduce the risk of type 2 diabetes in individuals with impaired glucose?

B. Smith, D.L. Wingard, T.C. Smith, D. Kritz-Silverstein, E. Barrett-Connor

Epidemiology/Health Services/Psychosocial Research

2391 Incidence of type 1 diabetes in Philadelphia is higher in black than white children from 1995 to 1999: epidemic or misclassification?

T.H. Lipman, A.F. Jawad, K.M. Murphy, A. Tuttle, R.L. Thompson, S.J. Ratcliffe, L.E. Levitt Katz

2396 Trends in hyperinsulinemia among nondiabetic adults in the U.S.

C. Li, E.S. Ford, L.C. McGuire, A.H. Mokdad, R.R. Little, G.M. Reaven

► **2403** Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study

J.A. Johnson, S.L. Pohar, S.R. Majumdar

2409 Age and sex may significantly interact with diabetes on the risks of lower-extremity amputation and peripheral

revascularization procedures: evidence from a cohort of a half-million diabetic patients

H.-F. Chen, C.-A. Ho, C.-Y. Li

2415 The burden and treatment of diabetes in elderly individuals in the U.S.

E. Selvin, J. Coresh, F.L. Brancati

2420 Design and validation of a population-based definition of the metabolic syndrome

C.A. Aguilar-Salinas, R. Rojas, C. Gonzalez-Villalpando, F.J. Gómez-Pérez, R. Mehta, G. Olaiz, J.A. Rull, D.R. Cox

2427 Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study

J.M. Lee, M.J. Okumura, M.M. Davis, W.H. Herman, J.G. Gurney

Emerging Treatments and Technologies

2433 Evaluation of a new measure of blood glucose variability in diabetes

B.P. Kovatchev, E. Otto, D. Cox, L. Gonder-Frederick, W. Clarke

Pathophysiology/Complications

2439 Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes

P.C.Y. Tong, A.P.S. Kong, W.-Y. So, M.H.L. Ng, X. Yang, M.C.Y. Ng, R.C.W. Ma, C.-S. Ho, C.W.K. Lam, C.-C. Chow, C.S. Cockram, J.C.N. Chan

2445 Combination of multiple genetic risk factors is synergistically associated with carotid atherosclerosis in Japanese subjects with type 2 diabetes

Y. Yamasaki, N. Katakami, K. Sakamoto, H. Kaneto, M. Matsuhisa, H. Sato, M. Hori, M. Haneda, A. Kashiwagi, Y. Tanaka, R. Kawamori, S. Kuno

2452 Clinical benefit of a gluten-free diet in type 1 diabetic children with screening-detected celiac disease: a population-based screening study with 2 years' follow-up

D. Hansen, B. Brock-Jacobsen, E. Lund, C. Bjørn, L.P. Hansen, C. Nielsen, C. Fenger, S.T. Lillevang, S. Husby

2457 Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes

Y.M. Cho, B.-S. Youn, H. Lee, N. Lee, S.-S. Min, S.H. Kwak, H.K. Lee, K.S. Park

2462 Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection

R. Simó, A. Lecube, J. Genescà, J.I. Esteban, C. Hernández

2467 Cigarette smoking is associated with low glomerular filtration rate in male patients with type 2 diabetes

S. De Cosmo, O. Lamacchia, A. Rauseo, R. Viti, L. Gesualdo, A. Pilotti, V. Trischitta, M. Cignarelli

Cardiovascular and Metabolic Risk

2471 Metabolic syndrome: prevalence and prediction of mortality in elderly individuals

G. Ravaglia, P. Forti, F. Maioli, L. Bastagli, M. Chiappelli, F. Montesi, L. Bolondi, C. Patterson

2477 Obese women and the relation between cardiovascular risk profile and hormone therapy, glucose tolerance, and psychosocial conditions

J. Lidfeldt, G. Samsioe, C.-D. Agardh

2483 Celiac disease and risk of subsequent type 1 diabetes: a general population cohort study of children and adolescents
J.F. Ludvigsson, J. Ludvigsson, A. Ekbom, S.M. Montgomery

2489 Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals
A. Tönjes, M. Scholz, M. Loeffler, M. Stumvoll

► **2498** Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study
M.B. Snijder, R.J. Heine, J.C. Seidell, L.M. Bouter, C.D.A. Stehouwer, G. Nijpels, T. Funahashi, Y. Matsuzawa, I. Shimomura, J.M. Dekker

Brief Reports

Clinical Care/Education/Nutrition

2504 Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients
P. Ballani, M.T. Tran, M.D. Navar, M.B. Davidson

2506 The natural history of LDL control in type 2 diabetes: a prospective study of adherence to lipid guidelines
D. Rucker, J.A. Johnson, T.K. Lee, D.T. Eurich, R.Z. Lewanczuk, S.H. Simpson, E.L. Toth, S.R. Majumdar

Pathophysiology/Complications

2509 Polymorphism of the 3'-untranslated region of the leptin receptor gene, but not the adiponectin SNP45 polymorphism, predicts type 2 diabetes: a population-based study
M. Nannipieri, R. Posadas, A. Bonotti, K. Williams, C. Gonzalez-Villalpando, M.P. Stern, E. Ferrannini

2512 HbA_{1c} values determine the outcome of intrasheath injection of triamcinolone for diabetic flexor tenosynovitis
M. Kameyama, O. Funae, S. Meguro, Y. Atsumi

Cardiovascular and Metabolic Risk

2515 Is the third component of metabolic syndrome really predictive of outcomes in type 2 diabetic patients?
M. Monami, L. Lambertucci, A. Ungar, M. Pieri, G. Masotti, N. Marchionni, E. Mannucci

Reviews/Commentaries/ADA Statements

► 2518 Meta-Analysis

Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis
N.J. Snowling, W.G. Hopkins

2528 Review

Type 1 diabetes and coronary artery disease
T.J. Orchard, T. Costacou, A. Kretowski, R.W. Nesto

2539 Review

Brain imaging in patients with diabetes: a systematic review
B. van Harten, F.-E. de Leeuw, H.C. Weinstein, P. Scheltens, G.J. Biessels

2549 Perspectives on the News

Glycemic treatment in type 1 and type 2 diabetes
Z.T. Bloomgarden

J.I. Botella-Carretero, M. Luque-Ramírez, F. Álvarez-Blasco, J.L.S. Millán, H.F. Escobar-Morreale

2556 On the weighted-average relationship between plasma glucose and HbA_{1c}
O.J. Gibson, P.E. McSharry, L. Tarassenko

2557 Is pregnancy outcome worse in type 2 than in type 1 diabetic women?
N. Hillman, L. Herranz, P.M. Vaquero, A. Villarroel, A. Fernandez, L.F. Pallardo

Letters: Comments and Responses

2558 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube et al.
U.V. Gentilucci, A. Picardi, P. Pozzilli

2559 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Gentilucci et al.
R. Simó

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
T.M.E. Davis, C.A. Cull, R.R. Holman

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Davis et al.
S. Fourlanos, L.C. Harrison, P.G. Colman

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp
I.F. Gazi, D.P. Mikhailidis

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Gazi and Mikhailidis
R.H. Knopp, on behalf of the ASPEN Study Group

2562 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Boyko et al.
G.P. Leese, A.D. Morris

2563 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Leese and Morris
E.J. Boyko, J.H. Ahroni, K.M. Nelson

2563 Standards of medical care in diabetes—2006: response to the American Diabetes Association
K.H. Tseng

2564 Standards of medical care in diabetes—2006: response to Tseng
V. Fonseca, N.G. Clark

2565 Does the metabolic syndrome exist? Response to Grundy
M.B. Davidson

2565 Does the metabolic syndrome exist? Response to Davidson
S.M. Grundy

2566 The metabolic syndrome (emperor) wears no clothes: response to Kahn
E. Oda

2566 The metabolic syndrome (emperor) wears no clothes: response to Oda
R. Kahn

Letters: Observations

2556 Mutations in the hereditary hemochromatosis gene are not associated with the increased body iron stores observed in overweight and obese women with polycystic ovary syndrome

J.I. Botella-Carretero, M. Luque-Ramírez, F. Álvarez-Blasco, J.L.S. Millán, H.F. Escobar-Morreale

O.J. Gibson, P.E. McSharry, L. Tarassenko

2557 Is pregnancy outcome worse in type 2 than in type 1 diabetic women?
N. Hillman, L. Herranz, P.M. Vaquero, A. Villarroel, A. Fernandez, L.F. Pallardo

Letters: Comments and Responses

2558 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube et al.
U.V. Gentilucci, A. Picardi, P. Pozzilli

2559 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Gentilucci et al.
R. Simó

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
T.M.E. Davis, C.A. Cull, R.R. Holman

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Davis et al.
S. Fourlanos, L.C. Harrison, P.G. Colman

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp
I.F. Gazi, D.P. Mikhailidis

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Gazi and Mikhailidis
R.H. Knopp, on behalf of the ASPEN Study Group

2562 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Boyko et al.
G.P. Leese, A.D. Morris

2563 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Leese and Morris
E.J. Boyko, J.H. Ahroni, K.M. Nelson

2563 Standards of medical care in diabetes—2006: response to the American Diabetes Association
K.H. Tseng

2564 Standards of medical care in diabetes—2006: response to Tseng
V. Fonseca, N.G. Clark

2565 Does the metabolic syndrome exist? Response to Grundy
M.B. Davidson

2565 Does the metabolic syndrome exist? Response to Davidson
S.M. Grundy

2566 The metabolic syndrome (emperor) wears no clothes: response to Kahn
E. Oda

2566 The metabolic syndrome (emperor) wears no clothes: response to Oda
R. Kahn

J.I. Botella-Carretero, M. Luque-Ramírez, F. Álvarez-Blasco, J.L.S. Millán, H.F. Escobar-Morreale

O.J. Gibson, P.E. McSharry, L. Tarassenko

2557 Is pregnancy outcome worse in type 2 than in type 1 diabetic women?
N. Hillman, L. Herranz, P.M. Vaquero, A. Villarroel, A. Fernandez, L.F. Pallardo

Letters: Comments and Responses

2558 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube et al.
U.V. Gentilucci, A. Picardi, P. Pozzilli

2559 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Gentilucci et al.
R. Simó

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
T.M.E. Davis, C.A. Cull, R.R. Holman

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Davis et al.
S. Fourlanos, L.C. Harrison, P.G. Colman

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp
I.F. Gazi, D.P. Mikhailidis

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Gazi and Mikhailidis
R.H. Knopp, on behalf of the ASPEN Study Group

2562 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Boyko et al.
G.P. Leese, A.D. Morris

2563 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Leese and Morris
E.J. Boyko, J.H. Ahroni, K.M. Nelson

2563 Standards of medical care in diabetes—2006: response to the American Diabetes Association
K.H. Tseng

2564 Standards of medical care in diabetes—2006: response to Tseng
V. Fonseca, N.G. Clark

2565 Does the metabolic syndrome exist? Response to Grundy
M.B. Davidson

2565 Does the metabolic syndrome exist? Response to Davidson
S.M. Grundy

2566 The metabolic syndrome (emperor) wears no clothes: response to Kahn
E. Oda

2566 The metabolic syndrome (emperor) wears no clothes: response to Oda
R. Kahn

J.I. Botella-Carretero, M. Luque-Ramírez, F. Álvarez-Blasco, J.L.S. Millán, H.F. Escobar-Morreale

O.J. Gibson, P.E. McSharry, L. Tarassenko

2557 Is pregnancy outcome worse in type 2 than in type 1 diabetic women?
N. Hillman, L. Herranz, P.M. Vaquero, A. Villarroel, A. Fernandez, L.F. Pallardo

Letters: Comments and Responses

2558 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube et al.
U.V. Gentilucci, A. Picardi, P. Pozzilli

2559 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Gentilucci et al.
R. Simó

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
T.M.E. Davis, C.A. Cull, R.R. Holman

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Davis et al.
S. Fourlanos, L.C. Harrison, P.G. Colman

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp
I.F. Gazi, D.P. Mikhailidis

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Gazi and Mikhailidis
R.H. Knopp, on behalf of the ASPEN Study Group

2562 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Boyko et al.
G.P. Leese, A.D. Morris

2563 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Leese and Morris
E.J. Boyko, J.H. Ahroni, K.M. Nelson

2563 Standards of medical care in diabetes—2006: response to the American Diabetes Association
K.H. Tseng

2564 Standards of medical care in diabetes—2006: response to Tseng
V. Fonseca, N.G. Clark

2565 Does the metabolic syndrome exist? Response to Grundy
M.B. Davidson

2565 Does the metabolic syndrome exist? Response to Davidson
S.M. Grundy

2566 The metabolic syndrome (emperor) wears no clothes: response to Kahn
E. Oda

2566 The metabolic syndrome (emperor) wears no clothes: response to Oda
R. Kahn

J.I. Botella-Carretero, M. Luque-Ramírez, F. Álvarez-Blasco, J.L.S. Millán, H.F. Escobar-Morreale

O.J. Gibson, P.E. McSharry, L. Tarassenko

2557 Is pregnancy outcome worse in type 2 than in type 1 diabetic women?
N. Hillman, L. Herranz, P.M. Vaquero, A. Villarroel, A. Fernandez, L.F. Pallardo

Letters: Comments and Responses

2558 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube et al.
U.V. Gentilucci, A. Picardi, P. Pozzilli

2559 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Gentilucci et al.
R. Simó

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
T.M.E. Davis, C.A. Cull, R.R. Holman

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Davis et al.
S. Fourlanos, L.C. Harrison, P.G. Colman

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp
I.F. Gazi, D.P. Mikhailidis

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Gazi and Mikhailidis
R.H. Knopp, on behalf of the ASPEN Study Group

2562 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Boyko et al.
G.P. Leese, A.D. Morris

2563 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Leese and Morris
E.J. Boyko, J.H. Ahroni, K.M. Nelson

2563 Standards of medical care in diabetes—2006: response to the American Diabetes Association
K.H. Tseng

2564 Standards of medical care in diabetes—2006: response to Tseng
V. Fonseca, N.G. Clark

2565 Does the metabolic syndrome exist? Response to Grundy
M.B. Davidson

2565 Does the metabolic syndrome exist? Response to Davidson
S.M. Grundy

2566 The metabolic syndrome (emperor) wears no clothes: response to Kahn
E. Oda

2566 The metabolic syndrome (emperor) wears no clothes: response to Oda
R. Kahn

J.I. Botella-Carretero, M. Luque-Ramírez, F. Álvarez-Blasco, J.L.S. Millán, H.F. Escobar-Morreale

O.J. Gibson, P.E. McSharry, L. Tarassenko

2557 Is pregnancy outcome worse in type 2 than in type 1 diabetic women?
N. Hillman, L. Herranz, P.M. Vaquero, A. Villarroel, A. Fernandez, L.F. Pallardo

Letters: Comments and Responses

2558 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube et al.
U.V. Gentilucci, A. Picardi, P. Pozzilli

2559 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Gentilucci et al.
R. Simó

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
T.M.E. Davis, C.A. Cull, R.R. Holman

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Davis et al.
S. Fourlanos, L.C. Harrison, P.G. Colman

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp
I.F. Gazi, D.P. Mikhailidis

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Gazi and Mikhailidis
R.H. Knopp, on behalf of the ASPEN Study Group

2562 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Boyko et al.
G.P. Leese, A.D. Morris

2563 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Leese and Morris
E.J. Boyko, J.H. Ahroni, K.M. Nelson

2563 Standards of medical care in diabetes—2006: response to the American Diabetes Association
K.H. Tseng

2564 Standards of medical care in diabetes—2006: response to Tseng
V. Fonseca, N.G. Clark

2565 Does the metabolic syndrome exist? Response to Grundy
M.B. Davidson

2565 Does the metabolic syndrome exist? Response to Davidson
S.M. Grundy

2566 The metabolic syndrome (emperor) wears no clothes: response to Kahn
E. Oda

2566 The metabolic syndrome (emperor) wears no clothes: response to Oda
R. Kahn

J.I. Botella-Carretero, M. Luque-Ramírez, F. Álvarez-Blasco, J.L.S. Millán, H.F. Escobar-Morreale

O.J. Gibson, P.E. McSharry, L. Tarassenko

2557 Is pregnancy outcome worse in type 2 than in type 1 diabetic women?
N. Hillman, L. Herranz, P.M. Vaquero, A. Villarroel, A. Fernandez, L.F. Pallardo

Letters: Comments and Responses

2558 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube et al.
U.V. Gentilucci, A. Picardi, P. Pozzilli

2559 Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Gentilucci et al.
R. Simó

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
T.M.E. Davis, C.A. Cull, R.R. Holman

2560 A clinical screening tool identifies autoimmune diabetes in adults: response to Davis et al.
S. Fourlanos, L.C. Harrison, P.G. Colman

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp
I.F. Gazi, D.P. Mikhailidis

2561 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Gazi and Mikhailidis
R.H. Knopp, on behalf of the ASPEN Study Group

2562 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Boyko et al.
G.P. Leese, A.D. Morris

2563 Prediction of diabetic foot ulcer occurrence using commonly available clinical information: response to Leese and Morris
E.J. Boyko, J.H. Ahroni, K.M. Nelson

2563 Standards of medical care in diabetes—2006: response to the American Diabetes Association
K.H. Tseng

2564 Standards of medical care in diabetes—2006: response to Tseng
V. Fonseca, N.G. Clark

2565 Does the metabolic syndrome exist? Response to Grundy
M.B.

2567 A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Nutrition Examination Survey 1999–2002: response to Lee et al.

M. Porta

2568 A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Nutrition Examination Survey 1999–2002: response to Porta

D.-H. Lee, D.R. Jacobs, Jr.

2569 Key Global Literature

2571 Errata

2572 Issues and Updates

2573 SI Units Table

2574 Classified Advertising